ML228 (ML-228; CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) which potently activate HIF in vitro as well as its downstream target VEGF.

1,4-DPCA is a novel, potent and competitive inhibitor of prolyl 4-hydroxylase with IC50 value of 3.6 μM.

EL102, a novel toluidine sulphonamide, is a novel inhibitor of HIF1α (hypoxia inducible factor) and can also potently inhibit tubulin polymerisation and decreased microtubule stability.

Adaptaquin is a novel and potent hydroxyquinoline inhibitor of HIF-PHD (hypoxia-inducible factor prolyl hydroxylase 2) with an IC50 of 2 μM.

JNJ-42041935 is a novel, potent, competitive, reversible, and selective inhibitor of prolyl hydroxylase PHD with pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09 for PHD1, PHD2, and PHD3, respectively.

Hydralazine HCl (Apresoline, Adrolazine , Apresrex), the hydrochloride salt of hydralazine, is a potent and direct-acting smooth muscle relaxant and vasodilator used for the treatment of hypertension.